Overview

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Rush University Medical Center
Treatments:
Thalidomide
Topotecan